Cart
sales@molnova.com
MPT0E028
CAS No. 1338320-94-7
MPT0E028( MPT0 E028 )
Catalog No. M11358 CAS No. 1338320-94-7
MPT0E028 (MPT 0E028) is a potent HDAC inhibitor that inhibits nuclear HDAC activity with IC50 of 11.1 nM in HeLa cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 223 | In Stock |
|
| 5MG | 202 | In Stock |
|
| 10MG | 297 | In Stock |
|
| 25MG | 629 | In Stock |
|
| 50MG | 925 | In Stock |
|
| 100MG | 1609 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMPT0E028
-
NoteResearch use only, not for human use.
-
Brief DescriptionMPT0E028 (MPT 0E028) is a potent HDAC inhibitor that inhibits nuclear HDAC activity with IC50 of 11.1 nM in HeLa cells.
-
DescriptionMPT0E028 (MPT 0E028) is a potent HDAC inhibitor that inhibits nuclear HDAC activity with IC50 of 11.1 nM in HeLa cells, 9-30 times more potent than SAHA; inhibits class I HDAC1, HDAC2, and class Iib HDAC6 with IC50 of 53, 106, and 29.5 nM, respectively, weakly inhibits HDAC8 (IC50=2.5 uM), but not for HDAC4 (IC50>10 uM); inhibits the growth of HCT116 and MDA-MB-231 cells with IC50 of 0.09 and 0.19 uM; inhibits HCT116 tumor xenograft in vivo without significant adverse effects, shows stronger anti-cancer efficacy than SAHA.Solid Tumors Phase 1 Clinical
-
In Vitro——
-
In Vivo——
-
SynonymsMPT0 E028
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC
-
Research AreaCancer
-
IndicationSolid Tumors
Chemical Information
-
CAS Number1338320-94-7
-
Formula Weight344.385
-
Molecular FormulaC17H16N2O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (290.38 mM)
-
SMILESO=C(NO)/C=C/C1=CC2=C(N(S(=O)(C3=CC=CC=C3)=O)CC2)C=C1
-
Chemical Name(E)-N-hydroxy-3-(1-(phenylsulfonyl)indolin-5-yl)acrylamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Huang HL, et al. PLoS One. 2012;7(8):e43645.
2. Chen MC, et al. Cell Death Dis. 2013 Sep 19;4:e810.
3. Chen CH, et al. Clin Cancer Res. 2014 Mar 1;20(5):1274-1287.
4. Huang HL, et al. Oncotarget. 2015 Mar 10;6(7):4976-91.
molnova catalog
related products
-
GSK-3117391
GSK-3117391 (CHR-5154) is a novel macrophage-targeted HDAC inhibitor.
-
HDACi-4b
A benzamide-type HDAC inhibitor with IC50 of 78 uM for changes of FXN mRNA in affected GM15850 cells.
-
1-Naphthohydroxamic ...
1-Naphthohydroxamic acid (Compound 2) is a potent and selective HDAC8 inhibitor with an IC50 of 14 μM, and it is more selectively for HDAC8 than class I HDAC1 and class II HDAC6 (IC50 >100 μM).
